Adverse events

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, Sauk JS. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the[...]

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

Özgüroğlu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage[...]

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatol[...]

Arshad MS, Jamil A, Greene SJ, Van Spall HGC, Fonarow GC, Butler J, Khan MS. In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute[...]

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin[...]

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak[...]

Russ-Jara AL, Elkhadragy N, Arthur KJ, DiIulio JB, Militello LG, Ifeachor AP, Glassman PA, Zillich AJ, Weiner M. Cognitive task analysis of clinicians' drug-drug interaction[...]

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March[...]